Bleeding Disorders Treatment Market: Top Factors Impacting The Growth Globally
Bleeding Disorders Treatment Market report categories the Global market by Drug Class (Plasma Derived and Recombinant Factor Concentrates, Fibrin Sealants and Others, Desmopressin, Antifibrinolytics), Type & Geography
(EMAILWIRE.COM, August 01, 2018 ) The global bleeding disorders treatment market is projected to reach USD 15.09 Billion by 2021 from USD 10.33 Billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The global market is broadly classified into type, drug class, and region.
Based on type, the bleeding disorders treatment market is segmented into hemophilia A, hemophilia B, Von Willebrand Disease (vWD), and others. The hemophilia A segment is projected to register the highest growth rate in the market. Market growth in this market segment is driven by the large number of patients suffering from hemophilia A and rising R&D investment for hemophilia product
Based on class of drug, the bleeding disorders treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
For the coming five years, APAC and LATAM regions are considered to be the lucrative markets for the bleeding disorders treatment market. Growth in this region can be attributed to increasing initiatives by local governments for increasing access to healthcare, rising disposable income, and increasing focus of global players towards emerging economies.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
This report aims to provide insights into the bleeding disorders treatment market. It provides valuable information on the market by type and by drug class, in the market. Furthermore, a geographical analysis for these segments is also presented in this report. Leading players in the market are profiled to study their product offerings and understand their strategies to remain competitive in this market.
The above-mentioned information would benefit the buyer by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize on the growth opportunities.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=71198026
Based on type, the bleeding disorders treatment market is segmented into hemophilia A, hemophilia B, Von Willebrand Disease (vWD), and others. The hemophilia A segment is projected to register the highest growth rate in the market. Market growth in this market segment is driven by the large number of patients suffering from hemophilia A and rising R&D investment for hemophilia product
Based on class of drug, the bleeding disorders treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
For the coming five years, APAC and LATAM regions are considered to be the lucrative markets for the bleeding disorders treatment market. Growth in this region can be attributed to increasing initiatives by local governments for increasing access to healthcare, rising disposable income, and increasing focus of global players towards emerging economies.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
This report aims to provide insights into the bleeding disorders treatment market. It provides valuable information on the market by type and by drug class, in the market. Furthermore, a geographical analysis for these segments is also presented in this report. Leading players in the market are profiled to study their product offerings and understand their strategies to remain competitive in this market.
The above-mentioned information would benefit the buyer by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize on the growth opportunities.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=71198026
Contact Information:
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results